S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Biden's Plan to Confiscate Your Cash? (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Biden's Plan to Confiscate Your Cash? (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Biden's Plan to Confiscate Your Cash? (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
S&P 500   4,274.04
DOW   33,980.32
QQQ   328.49
Agilent Technologies Proves Its Worth VS Illumina 
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Target’s Results Cap Upside Potential For Retail Stocks 
Wind energy boom and golden eagles collide in the US West
Lowe’s Stands Out Amid Q2 Retail Reports 
Biden's Plan to Confiscate Your Cash? (Ad)
Egypt's central bank governor resigns as economic woes mount
Target takes a hit after heavy discounts to clear inventory
Stocks slip on Wall Street, erasing weekly gains for S&P 500
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
NASDAQ:EOLS

Evolus - EOLS Insider Trading & Ownership

$10.06
+0.25 (+2.55%)
(As of 08/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$9.61
$10.10
50-Day Range
$8.95
$13.72
52-Week Range
$5.06
$14.34
Volume
438,745 shs
Average Volume
522,155 shs
Market Capitalization
$564.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.33

Evolus (NASDAQ:EOLS) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
7.30%
Number Of
Insiders Buying
(Last 12 Months)
1
Amount Of
Insider Buying
(Last 12 Months)
$1.47 M
Number Of
Insiders Selling
(Last 12 Months)
7
Amount Of
Insider Selling
(Last 12 Months)
$27.48 M

EOLS Insider Buying and Selling by Quarter

Get EOLS Insider Trade Alerts

Want to know when executives and insiders are buying or selling Evolus stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.


Evolus Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2022Medytox Inc.Major ShareholderSell26,000$13.28$345,280.007,437,652  
5/18/2022Lauren P SilvernailInsiderSell52,015$12.42$646,026.30141,571  
5/16/2022David MoatazediInsiderSell55,321$13.64$754,578.44491,961  
5/16/2022David N GillDirectorSell5,000$13.62$68,100.0029,568  
5/13/2022David N GillDirectorSell5,313$13.10$69,600.3034,568  
3/28/2022David MoatazediInsiderSell6,104$11.62$70,928.48  
3/8/2022Crystal MuilenburgCMOSell6,495$9.73$63,196.35  
3/8/2022David MoatazediInsiderSell37,972$9.73$369,467.56  
9/2/2021Alphaeon 1 LlcMajor ShareholderSell2,597,475$9.50$24,676,012.506,064,871  
8/25/2021Medytox Inc.Major ShareholderBuy44,000$11.12$489,280.007,346,652  
8/23/2021Vikram MalikDirectorSell26,077$11.00$286,847.00  
8/20/2021Medytox Inc.Major ShareholderBuy48,000$10.56$506,880.007,112,652  
8/19/2021Vikram MalikDirectorSell11,962$10.50$125,601.00  
8/18/2021Medytox Inc.Major ShareholderBuy45,000$10.54$474,300.007,012,652  
8/17/2021Vikram MalikDirectorSell42,083$10.06$423,354.98  
8/16/2021David MoatazediInsiderSell47,737$11.35$541,814.95424,809  
8/13/2021David MoatazediInsiderSell22,708$10.66$242,067.28  
8/10/2021Rui AvelarInsiderSell14,293$11.18$159,795.74209,810  
1/25/2021Lauren P SilvernailInsiderSell2,699$7.46$20,134.5490,689  
1/7/2020Rui AvelarInsiderSell39,442$10.71$422,423.8270,802  
6/13/2019David N GillDirectorBuy2,000$13.65$27,300.00  
6/3/2019Vikram MalikDirectorBuy1,298,701$19.25$24,999,994.25  
5/31/2019Lauren P SilvernailInsiderSell2,612$13.53$35,340.36  
5/29/2019Kristine RomineDirectorBuy2,090$14.77$30,869.30  
5/22/2019Corp AlphaeonMajor ShareholderSell5,307,940$19.25$102,177,845.00  
5/20/2019Simone BlankDirectorBuy628,536$19.25$12,099,318.00  
12/17/2018Vikram MalikDirectorBuy7,800$13.04$101,712.00  
12/14/2018David N GillDirectorBuy3,000$12.77$38,310.00  
11/29/2018Corp AlphaeonMajor ShareholderSell573,888$14.00$8,034,432.00  
11/29/2018Kristine RomineDirectorBuy6,347$14.00$88,858.00  
9/14/2018Michael M JafarInsiderBuy12,800$20.83$266,624.00  
8/22/2018Kristine RomineDirectorBuy10,000$19.83$198,300.00  
7/23/2018Corp AlphaeonMajor ShareholderSell1,000,000$18.80$18,800,000.00  
6/14/2018Vikram MalikDirectorBuy8,600$28.88$248,368.00  
6/8/2018Kristine RomineDirectorBuy2,200$28.54$62,788.00  
6/6/2018Bosun HauDirectorBuy2,898$34.94$101,256.12  
6/4/2018Bosun HauDirectorBuy7,142$29.19$208,474.98  
6/1/2018Kristine RomineDirectorBuy7,000$25.16$176,120.00  
(Data available from 1/1/2013 forward)












EOLS Insider Trading Activity - Frequently Asked Questions

Who is on Evolus's Insider Roster?

The list of insiders at Evolus includes Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Lauren P Silvernail, Medytox Inc., Rui Avelar, and Vikram Malik. Learn more on insiders at EOLS.

What percentage of Evolus stock is owned by insiders?

7.30% of Evolus stock is owned by insiders. Learn more on EOLS's insider holdings.

Which Evolus insiders have been buying company stock?

The following insider purchased EOLS shares in the last 24 months: Medytox Inc. ($1,470,460.00).

How much insider buying is happening at Evolus?

Insiders have purchased a total of 137,000 EOLS shares in the last 24 months for a total of $1,470,460.00 bought.

Which Evolus insiders have been selling company stock?

The following insiders have sold EOLS shares in the last 24 months: Alphaeon 1 Llc ($24,676,012.50), Crystal Muilenburg ($63,196.35), David Moatazedi ($1,978,856.71), David N Gill ($137,700.30), Lauren P Silvernail ($666,160.84), Medytox Inc. ($345,280.00), Rui Avelar ($159,795.74), and Vikram Malik ($835,802.98).

How much insider selling is happening at Evolus?

Insiders have sold a total of 2,959,254 Evolus shares in the last 24 months for a total of $28,862,805.42 sold.

This page (NASDAQ:EOLS) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.